https://www.onclive.com/view/sequencing-b7-h4-targeted-adcs-and-optimizing-toxicity-management-in-gynecologic-cancers2026-10-14T20:11:00Z2026-10-14T20:11:00Z https://www.onclive.com/view/elevar-resubmits-nda-for-rivoceranib-plus-camrelizumab-frontline-unresectable-metastatic-hcc2026-10-14T18:09:20.314Z2026-10-14T18:09:20.314Z https://www.onclive.com/view/dr-goetz-on-the-development-of-novel-approaches-in-endocrine-resistant-hr-breast-cancer2026-10-14T17:30:00Z2026-10-14T17:30:00Z https://www.onclive.com/view/fda-approves-immunotherapy-regimen-studied-by-mayo-clinic-for-stage-3-colon-cancer2026-10-14T16:00:00Z2026-10-14T16:00:00Z https://www.onclive.com/view/fda-approves-nogapendekin-alfa-inbakicept-plus-bcg-for-high-grade-papillary-only-bcg-unresponsive-nmibc2026-10-14T15:26:23.452Z2026-10-14T15:26:23.452Z https://www.onclive.com/view/dr-goetz-on-the-navigation-of-oral-serds-and-targeted-therapy-in-advanced-breast-cancer2026-10-14T14:47:36.447Z2026-10-14T14:47:36.447Z https://www.onclive.com/view/the-next-wave-adcs-targeted-therapies-and-emerging-strategies-in-ovarian-cancer2026-10-14T14:20:00Z2026-10-14T14:20:00Z https://www.onclive.com/view/fda-accepts-bla-resubmission-for-tabelecleucel-in-ebv-post-transplant-lymphoproliferative-disease2026-10-14T14:05:58.507Z2026-10-14T14:05:58.507Z https://www.onclive.com/view/long-term-and-novel-adc-data-dominate-top-gynecologic-cancer-abstracts-at-esmo-20262026-10-14T13:00:00Z2026-10-14T13:00:00Z https://www.onclive.com/view/closing-remarks-and-emerging-data-outlook2026-10-14T12:10:00Z2026-10-14T12:10:00Z https://www.onclive.com/view/treatment-sequencing-and-closing-remarks2026-10-14T12:06:00Z2026-10-14T12:06:00Z https://www.onclive.com/view/toxicity-management-in-squamous-nsclc2026-10-14T12:05:00Z2026-10-14T12:05:00Z https://www.onclive.com/view/key-takeaways-on-infection-risk-in-cll-treatment-selection2026-10-14T12:05:00Z2026-10-14T12:05:00Z https://www.onclive.com/view/post-immunotherapy-treatment-in-advanced-renal-cell-carcinoma2026-10-14T12:05:00Z2026-10-14T12:05:00Z https://www.onclive.com/view/off-the-shelf-therapies-combination-strategies-and-patient-centered-treatment-in-relapsed-refractory-multiple-myeloma2026-10-14T12:05:00Z2026-10-14T12:05:00Z https://www.onclive.com/view/key-takeaways-on-kras-g12c-management2026-10-14T12:05:00Z2026-10-14T12:05:00Z https://www.onclive.com/view/teclistamab-in-early-relapse-multiple-myeloma2026-10-14T12:05:00Z2026-10-14T12:05:00Z https://www.onclive.com/view/individualizing-treatment-selection-in-steroid-refractory-chronic-gvhd2026-10-14T12:05:00Z2026-10-14T12:05:00Z https://www.onclive.com/view/multidisciplinary-care-across-nodular-and-diffuse-tgct2026-10-14T12:05:00Z2026-10-14T12:05:00Z https://www.onclive.com/view/comparing-vimseltinib-and-pexidartinib-and-measuring-functional-outcomes-with-promis2026-10-14T12:03:00Z2026-10-14T12:03:00Z https://www.onclive.com/view/phase-3-motion-trial-efficacy-and-safety2026-10-14T12:02:00Z2026-10-14T12:02:00Z https://www.onclive.com/view/classifying-localized-vs-diffuse-tgct-and-deciding-who-needs-surgery-first2026-10-14T12:01:00Z2026-10-14T12:01:00Z https://www.onclive.com/view/patient-factors-help-individualize-adjuvant-endocrine-therapy-and-cdk4-6-inhibitor-use-in-hr-breast-cancer2026-10-14T12:00:00Z2026-10-14T12:00:00Z https://www.onclive.com/view/treatment-selection-at-early-relapse-in-multiple-myeloma2026-10-14T12:00:00Z2026-10-14T12:00:00Z https://www.onclive.com/view/high-risk-disease-and-treatment-selection-in-relapsed-refractory-multiple-myeloma2026-10-14T12:00:00Z2026-10-14T12:00:00Z https://www.onclive.com/view/weighing-real-world-data-on-infection-risk-in-cll2026-10-14T12:00:00Z2026-10-14T12:00:00Z https://www.onclive.com/view/treatment-selection-in-fh-deficient-renal-cell-carcinoma2026-10-14T12:00:00Z2026-10-14T12:00:00Z https://www.onclive.com/view/next-generation-kras-inhibitors-and-practice-change2026-10-14T12:00:00Z2026-10-14T12:00:00Z https://www.onclive.com/view/axatilimab-a-csf1r-directed-approach-to-inflammation-and-fibrosis2026-10-14T12:00:00Z2026-10-14T12:00:00Z https://www.onclive.com/view/ctla-4-directed-therapy-in-squamous-nsclc2026-10-14T12:00:00Z2026-10-14T12:00:00Z https://www.onclive.com/view/real-world-first-line-io-based-combos-are-associated-with-improved-os-vs-tki-monotherapy-in-advanced-rcc2026-10-13T20:40:43.981Z2026-10-13T20:40:43.981Z https://www.onclive.com/view/tenumomeran-raplemomeran-plus-pembrolizumab-misses-pfs-end-point-in-hpv16-hnscc2026-10-13T19:54:13.120Z2026-10-13T19:54:13.120Z https://www.onclive.com/view/cdk4-6-inhibitors-anchor-first-line-metastatic-breast-cancer-care-but-oral-serds-may-fall-short2026-10-13T16:05:00Z2026-10-13T16:05:00Z https://www.onclive.com/view/ai-assisted-scoping-review-of-code-sharing-in-clinical-prediction-model-research2026-10-13T16:00:00Z2026-10-13T16:00:00Z https://www.onclive.com/view/long-term-expectations-and-real-world-generalizability-of-copernicus2026-10-13T12:05:00Z2026-10-13T12:05:00Z https://www.onclive.com/view/earlier-car-t-cell-therapy-use-highlights-sequencing-and-access-considerations-in-myeloma2026-10-13T12:00:00Z2026-10-13T12:00:00Z https://www.onclive.com/view/destiny-breast05-and-post-neoadjuvant-her2-positive-early-breast-cancer2026-10-13T12:00:00Z2026-10-13T12:00:00Z https://www.onclive.com/view/pragmatic-design-and-early-safety-results-from-copernicus2026-10-13T12:00:00Z2026-10-13T12:00:00Z https://www.onclive.com/view/poll-results-highlight-breast-cancer-abstracts-of-interest-at-esmo-20262026-10-12T22:40:00Z2026-10-12T22:40:00Z https://www.onclive.com/view/dr-hansen-on-the-integration-of-car-t-cell-therapy-into-earlier-myeloma-treatment-lines2026-10-12T19:39:01.907Z2026-10-12T19:39:01.907Z https://www.onclive.com/view/fda-grants-fast-track-designation-to-opamtistomig-for-advanced-biliary-tract-cancer2026-10-12T18:20:10.910Z2026-10-12T18:20:10.910Z https://www.onclive.com/view/roswell-park-earns-national-ama-joy-in-medicine-recognition-for-advancing-physician-well-being2026-10-12T16:00:00Z2026-10-12T16:00:00Z https://www.onclive.com/view/dr-fradley-on-real-world-atrial-fibrillation-and-cardiovascular-outcomes-in-cll2026-10-12T15:53:16.447Z2026-10-12T15:53:16.447Z https://www.onclive.com/view/ryz101-meets-primary-pfs-end-point-in-phase-3-action-1-trial-for-post-lutetium-177-gep-nets2026-10-12T15:00:00Z2026-10-12T15:00:00Z https://www.onclive.com/view/cam-a-terminology-requiring-relegation-to-the-historical-wastebasket2026-10-12T14:00:00Z2026-10-12T14:00:00Z https://www.onclive.com/view/proactive-diarrhea-management-with-zanidatamab-based-regimens2026-10-12T12:05:00Z2026-10-12T12:05:00Z https://www.onclive.com/view/armenia-grants-first-marketing-authorizations-to-botensilimab-plus-balstilimab-in-previously-treated-mss-mcrc2026-10-12T12:00:00Z2026-10-12T12:00:00Z https://www.onclive.com/view/interpreting-pd-l1-subgroups-and-the-case-for-the-triplet-in-her2-positive-gea2026-10-12T12:00:00Z2026-10-12T12:00:00Z https://www.onclive.com/view/intensifying-conditioning-in-older-patients-and-unanswered-questions-in-allogeneic-transplant2026-10-12T12:00:00Z2026-10-12T12:00:00Z https://www.onclive.com/view/five-under-5-top-oncology-videos-for-the-week-of-10-5-20262026-10-11T12:00:00Z2026-10-11T12:00:00Z https://www.onclive.com/view/gi-cancer-monthly-rewind-key-news-and-expert-insights-you-may-have-missed-in-september-20262026-10-11T10:00:00Z2026-10-11T10:00:00Z https://www.onclive.com/view/the-oncfive-top-oncology-articles-for-the-week-of-10-4-20262026-10-10T12:00:00Z2026-10-10T12:00:00Z https://www.onclive.com/view/fda-flashback-hematologic-cancer-decisions-and-news-from-september-20262026-10-10T10:00:00Z2026-10-10T10:00:00Z https://www.onclive.com/view/dr-sinicrope-on-the-fda-approval-of-atezolizumab-plus-chemo-for-colon-cancer2026-10-10T00:00:00Z2026-10-10T00:00:00Z https://www.onclive.com/view/guardant360-cdx-receives-european-approval-as-companion-diagnostic-for-camizestrant-in-esr1-mutated-advanced-breast-cancer2026-10-09T21:30:00Z2026-10-09T21:30:00Z https://www.onclive.com/view/navigating-patient-centric-treatment-administration-strategies-in-myeloma2026-10-09T19:21:18.544Z2026-10-09T19:21:18.544Z https://www.onclive.com/view/fda-grants-fast-track-designation-to-psv359-for-advanced-fap-positive-solitary-fibrous-tumors2026-10-09T18:10:30.130Z2026-10-09T18:10:30.130Z https://www.onclive.com/view/targeted-approaches-in-pancreatic-cancer-chemo-intensification-in-crc-take-center-stage-as-key-gi-oncology-presentations-at-esmo-20262026-10-09T18:00:00Z2026-10-09T18:00:00Z https://www.onclive.com/view/ucsf-health-reaches-25-000-robotic-surgeries2026-10-09T16:00:00Z2026-10-09T16:00:00Z https://www.onclive.com/view/fda-grants-breakthrough-device-designation-to-natera-s-multi-cancer-early-detection-assay2026-10-09T15:08:59.207Z2026-10-09T15:08:59.207Z https://www.onclive.com/view/next-generation-nampt-inhibitors-aim-to-revive-a-stalled-target-in-aml-and-mds2026-10-09T14:00:00Z2026-10-09T14:00:00Z https://www.onclive.com/view/met-as-an-actionable-resistance-mechanism-new-randomized-data-and-what-it-means2026-10-09T12:05:00Z2026-10-09T12:05:00Z https://www.onclive.com/view/onclive-weekly-news-quiz-10-9-2026-did-you-miss-crucial-colon-cancer-myeloma-breast-cancer-and-lung-cancer-updates-2026-10-09T12:00:00Z2026-10-09T12:00:00Z https://www.onclive.com/view/progressing-on-frontline-therapy-resistance-mechanisms-and-second-line-options2026-10-09T12:00:00Z2026-10-09T12:00:00Z https://www.onclive.com/view/dr-hamilton-on-maintenance-tucatinib-based-therapy-for-her2-breast-cancer2026-10-09T00:00:00Z2026-10-09T00:00:00Z https://www.onclive.com/view/maverick-b7-h3-directed-adcs-and-adaura-data-headline-key-lung-cancer-findings-from-wclc-20262026-10-08T20:32:00Z2026-10-08T20:32:00Z https://www.onclive.com/view/dr-chae-on-the-differences-between-tumor-informed-and-tissue-agnostic-assays-in-nsclc2026-10-08T18:45:00Z2026-10-08T18:45:00Z https://www.onclive.com/view/fda-approves-atezolizumab-plus-chemo-for-stage-iii-dmmr-colon-cancer2026-10-08T17:50:49.569Z2026-10-08T17:50:49.569Z https://www.onclive.com/view/vir-5500-receives-fda-fast-track-designation-in-mcrpc2026-10-08T17:15:51.682Z2026-10-08T17:15:51.682Z https://www.onclive.com/view/new-statewide-plan-aims-to-eliminate-cervical-cancer-in-texas-by-20322026-10-08T16:00:00Z2026-10-08T16:00:00Z https://www.onclive.com/view/china-s-nmpa-approves-dato-dxd-for-metastatic-tnbc-ineligible-for-pd--l-1-inhibition2026-10-08T15:57:14.102Z2026-10-08T15:57:14.102Z https://www.onclive.com/view/iberdomide-plus-daratumumab-dexamethasone-yields-significant-pfs-benefit-in-r-r-myeloma2026-10-08T15:29:12.351Z2026-10-08T15:29:12.351Z https://www.onclive.com/view/china-s-nmpa-approves-adjuvant-t-dxd-for-her2-early-breast-cancer-with-residual-invasive-disease2026-10-08T15:00:00Z2026-10-08T15:00:00Z https://www.onclive.com/view/breast-cancer-monthly-rewind-key-news-and-expert-insights-you-may-have-missed-in-september-20262026-10-08T13:00:00Z2026-10-08T13:00:00Z https://www.onclive.com/view/individualized-neoantigen-vaccine-elicits-durable-t-cell-responses-in-resected-hpv-hnscc2026-10-08T12:00:00Z2026-10-08T12:00:00Z https://www.onclive.com/view/nonrelapse-mortality-safety-and-long-term-trajectory-after-gvhd-control2026-10-08T12:00:00Z2026-10-08T12:00:00Z https://www.onclive.com/view/novel-mek-inhibitor-research-aims-to-balance-efficacy-and-tolerability-in-pancreatic-cancer2026-10-07T22:00:00Z2026-10-07T22:00:00Z https://www.onclive.com/view/september-roundup-of-fda-approvals-in-oncology-8-decisions-to-know2026-10-07T19:47:34.043Z2026-10-07T19:47:34.043Z https://www.onclive.com/view/fda-approves-tucatinib-plus-trastuzumab-pertuzumab-as-first-line-maintenance-in-advanced-her2-breast-cancer2026-10-07T17:16:59.577Z2026-10-07T17:16:59.577Z https://www.onclive.com/view/fda-grants-breakthrough-therapy-designation-to-temab-a-in-previously-treated-c-met-expressing-nonsquamous-nsclc2026-10-07T16:25:00Z2026-10-07T16:25:00Z https://www.onclive.com/view/two-dana-farber-researchers-receive-prestigious-new-innovator-award-from-the-national-institutes-of-health2026-10-07T16:00:00Z2026-10-07T16:00:00Z https://www.onclive.com/view/fda-grants-breakthrough-therapy-designation-to-telisotuzumab-adizutecan-plus-bevacizumab-in-refractory-mcrc2026-10-07T14:55:00Z2026-10-07T14:55:00Z https://www.onclive.com/view/meta-analysis-shows-ropeginterferon-alfa-2b-benefit-over-phlebotomy-but-not-hydroxyurea-in2026-10-07T13:00:00Z2026-10-07T13:00:00Z https://www.onclive.com/view/belumosudil-and-the-evolving-role-of-ibrutinib-in-chronic-gvhd2026-10-07T12:05:00Z2026-10-07T12:05:00Z https://www.onclive.com/view/genomic-testing-in-squamous-nsclc2026-10-07T12:05:00Z2026-10-07T12:05:00Z https://www.onclive.com/view/clinical-data-and-practical-considerations-for-bcma-directed-antibody-drug-conjugates-in-relapsed-refractory-multiple-myeloma2026-10-07T12:05:00Z2026-10-07T12:05:00Z https://www.onclive.com/view/emerging-treatment-strategies-in-non-clear-cell-renal-cell-carcinom2026-10-07T12:05:00Z2026-10-07T12:05:00Z https://www.onclive.com/view/comparing-sotorasib-and-adagrasib-tolerability2026-10-07T12:05:00Z2026-10-07T12:05:00Z https://www.onclive.com/view/why-infection-rates-are-similar-across-btk-inhibitors2026-10-07T12:05:00Z2026-10-07T12:05:00Z https://www.onclive.com/view/long-term-treatment-burden-in-multiple-myeloma2026-10-07T12:05:00Z2026-10-07T12:05:00Z https://www.onclive.com/view/etentamig-iberdomide-and-long-term-perseus-data-headline-key-myeloma-findings-from-ims-20262026-10-07T12:00:00Z2026-10-07T12:00:00Z https://www.onclive.com/view/counseling-patients-on-ruxolitinib-expectations-response-and-the-extended-release-shift2026-10-07T12:00:00Z2026-10-07T12:00:00Z https://www.onclive.com/view/durability-and-depth-of-response-with-bcma-directed-bispecific-antibodies-in-relapsed-refractory-multiple-myeloma2026-10-07T12:00:00Z2026-10-07T12:00:00Z https://www.onclive.com/view/ighv-and-tp53-status-in-choosing-fixed-duration-vs-continuous-therapy2026-10-07T12:00:00Z2026-10-07T12:00:00Z https://www.onclive.com/view/emerging-kras-g12c-inhibitors-in-development2026-10-07T12:00:00Z2026-10-07T12:00:00Z https://www.onclive.com/view/treatment-considerations-in-non-clear-cell-renal-cell-carcinom2026-10-07T12:00:00Z2026-10-07T12:00:00Z https://www.onclive.com/view/mrd-assessment-in-multiple-myeloma2026-10-07T12:00:00Z2026-10-07T12:00:00Z https://www.onclive.com/view/emerging-therapies-in-squamous-nsclc2026-10-07T12:00:00Z2026-10-07T12:00:00Z https://www.onclive.com/view/dr-peters-on-combining-antiangiogenic-activity-with-checkpoint-inhibition-in-nsclc2026-10-06T21:51:00Z2026-10-06T21:51:00Z https://www.onclive.com/view/breast-cancer-survivorship-care-demands-rigorous-systemic-change2026-10-06T20:25:00Z2026-10-06T20:25:00Z